In the treatment of diseases, due to the characteristics of PARP1 in various DNA repair pathways and maintains the characteristics of genomic stability, it is expected to use small molecules inhibiting the enzyme activity to prevent unwanted DNA repair in the treatment of various cancers, including ovarian cancer, breast cancer, and prostate cancer.